SCHEMBL1925694

SCHEMBL1925694

N#Cc1ncn2c(C(F)(F)F)cc(-c3cccc(Cl)c3)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 5/20 0.42
CTSK P43235 4/20 0.42
TP53 P04637 1/20 0.38
ALOX15 P16050 1/20 0.37
ADORA1 P30542 2/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
MAPK13 O15264 1/20 0.36
DYRK3 O43781 1/20 0.36
MAP4K4 O95819 1/20 0.36
FYN P06241 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR1 P11362 1/20 0.36
SRC P12931 1/20 0.36
CSNK1D P48730 1/20 0.36
CLK2 P49760 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924945 0.88 CTSK (0.54) CTSSCTSKTP53KDM4EALDH1A1
SCHEMBL1924168 0.87 ALDH1A1 (0.48) TP53ADORA1ADORA2AKDM4EALDH1A1
SCHEMBL1924278 0.87 KDM4E (0.46) CTSSCTSKTP53KDM4EALDH1A1
SCHEMBL1924754 0.86 CTSS (0.42) CTSSCTSKTP53ADORA1ADORA2A
SCHEMBL1924987 0.82 KDM4E (0.39) ADORA1ADORA2AKDM4EALDH1A1HPGD
SCHEMBL1924221 0.82 KDM4E (0.42) CTSSTP53ALOX15ADORA2AKDM4E
SCHEMBL312753 0.81 CTSS (0.43) CTSSCTSKTP53ADORA2AKDM4E
SCHEMBL1923924 0.81 CTSS (0.38) CTSSCTSKTP53KDM4EALDH1A1
SCHEMBL1924030 0.81 CTSS (0.48) CTSSCTSK
SCHEMBL1924015 0.81 ADORA2A (0.40) CTSSCTSKALOX15ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7514443-B2 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors HOFFMANN-LA ROCHE INC. (US) 2009-04-07 US disclosed
US-20080051421-A1 Pyrazolo-pyridine WICHMANN JUERGEN 2008-02-28 US disclosed
US-7329662-B2 Pyrazolo-pyridine HOFFMANN-LA ROCHE INC. (US) 2008-02-12 US disclosed
CN-1890242-A Pyrazolo and imidazo-pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-01-03 CN disclosed
EP-1670801-A1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2006-06-21 EP disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 US disclosed
WO-2005040171-A1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR CTSS 2730/4885CTSK 2029/4885TP53 3056/4885
US-20080051421-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR CTSS 2730/4885CTSK 2029/4885TP53 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.